Primrose Bio’s Post

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/1HNr30sEIRr #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/6TYg30sFbHY #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/26O530sEOfy #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/C3W030sEI6q #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

Phase I data for Biohaven's lead IgG protein degrader failed to live up to investor expectations, sending shares plunging more than 12%, despite the company touting the results as "positive." https://lnkd.in/d-hcDPYJ #Biohaven #biotechnology #clinicalresearch #drugdevelopment #immunology #medicalaffairs #pharmaceuticals

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/ea0o30sELT3 #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

The Department of Science and Innovation (DSI) understands that impactful innovations require more than just great ideas—they need scalable means to make a real difference. Through open, mutually beneficial partnerships, we growing our health sector to meet the needs of society. One shining example is our 2003 public-private partnership with Biovac, a pharmaceutical manufacturing business. Now, with a $5 million grant from the Bill and Melinda Gates Foundation, Biovac is pioneering mRNA vaccines to combat diseases like tuberculosis, malaria, and Lassa fever. Together, we're saving lives and shaping the future of healthcare. Talk to us and find out more. Making sure it is possible. https://lnkd.in/dyuwAfQ2 #InnovationChampions #HealthcareResilience #SelfSufficiency #Innovation #VaccineManufacturing #Collaboration #Biotechnology #GlobalHealth #VaccineInnovation #LocalManufacturing #Biopharmaceutical #PharmaManufacturers #ChildVaccination #HospitalNetworks #DSI #Biovac #Pharmacy

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/hskx30sEHXW #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

Discover the future of vaccine technology and the role of next-generation adjuvants in the new edition of Pharma Insights! Learn how adjuvants enhance immune responses and drive vaccine efficacy. Click here: https://ow.ly/w5gl30sELZB #CrodaPharma #EmpoweringBiologicsDelivery #VaccineAdjuvants #PharmaInsights

𝗩𝗮𝘅𝗰𝘆𝘁𝗲 𝗽𝗿𝗶𝗰𝗲𝘀 $𝟳𝟱𝟬𝗠 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴, 𝗼𝗻𝗲 𝗼𝗳 𝗯𝗶𝗼𝘁𝗲𝗰𝗵’𝘀 𝗹𝗮𝗿𝗴𝗲𝘀𝘁, 𝗮𝘀 𝗶𝘁 𝗴𝗼𝗲𝘀 𝘂𝗽 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗕𝗶𝗴 𝗣𝗵𝗮𝗿𝗺𝗮'𝘀 𝗽𝗻𝗲𝘂𝗺𝗼𝗰𝗼𝗰𝗰𝗮𝗹 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀 It’ll take a lot of capital and resources to go up against Pfizer, Merck Group, GSK, Sanofi and others in the pneumococcal vaccine field. So, San Carlos, CA-based Vaxcyte will seek one of the largest public offerings in recent biotech memory. Vaxcyte’s request for $750 million, in an offering priced late Tuesday night, would rival only a few other biopharmas who have gone back to the market for additional financing on the heels of big data readouts or plans for large, late-stage studies. European drugmaker argenx hauled in nearly $1.3 billion last summer, and schizophrenia biotech Karuna Therapeutics , now being bought by Bristol Myers Squibb, secured $862 million in an August 2022 public offering. Grant Pickering, CEO of Vaxcyte pictured. https://lnkd.in/dvKu5eVT